Issue of Teratogenicity
Teratogenicity, or the potential of a substance to cause defects in a developing fetus, is a critical concern when managing anesthesia in pregnant patients. A teratogen is defined as a substance that increases the incidence of a specific fetal defect beyond what could be attributed to chance alone. To be teratogenic, an agent must be present in a sufficient dose, over a substantial period, and at a critical point in fetal development. The baseline incidence of congenital anomalies in the human population is approximately 3%, and this must be considered when evaluating the potential teratogenicity of anesthetic agents. Furthermore, physiological disturbances like hypoxia, hypercarbia, stress, and hypotension — which can occur during anesthesia and surgery — may also have teratogenic effects, complicating the risk assessment.
Certain anesthetic agents, such as nitrous oxide (N₂O), have been linked to teratogenic effects in animal studies. N₂O inhibits methionine synthase, a key enzyme for DNA synthesis, and high concentrations given over extended periods have shown teratogenic effects in animal models. However, such doses are not typically used in clinical practice, and while some clinicians choose to avoid N₂O in pregnant patients, there is no definitive evidence of harm in humans. The availability of alternative anesthetic options makes the use of N₂O less common in modern practice.
General anesthetic drugs that inhibit synaptic transmission can potentially disrupt synaptogenesis and induce inappropriate apoptosis, particularly during the rapid synaptogenesis phase from mid-gestation to several years post-birth. Although no conclusive evidence links volatile anesthetics to teratogenic effects in humans, it remains prudent to use the lowest effective concentrations for the shortest duration to avoid maternal hypotension and its adverse effects on fetal development. While benzodiazepines were once thought to be associated with cleft palate and cardiac anomalies, recent controlled studies have found no definitive link to these outcomes.
Nonetheless, benzodiazepines are generally avoided, particularly in the first trimester, unless necessary for preoperative anxiolysis to prevent maternal stress and compromised uteroplacental perfusion. Most other anesthetic medications, including barbiturates, propofol, opioids, muscle relaxants, and local anesthetics, have been widely used during pregnancy with a generally favorable safety profile, although subtle associations cannot be completely ruled out.
Maternal Factors Linked to Fetal Compromise
Maternal physiological changes can directly affect fetal well-being, particularly due to the lack of autoregulation in the uteroplacental circulation. Any reduction in maternal arterial pressure can compromise uteroplacental blood flow, leading to fetal ischemia. Maintaining maternal blood pressure is therefore crucial, often necessitating liberal intravenous fluid administration, except in cases of severe maternal cardiac or renal disease. Both ephedrine and phenylephrine are considered safe and effective vasopressors for managing maternal hypotension during pregnancy.
Fetal hemoglobin's high affinity for oxygen allows transient maternal hypoxemia to be well tolerated by the fetus. However, prolonged or significant maternal hypoxia can cause uteroplacental vasoconstriction, reducing perfusion and leading to fetal hypoxia, acidosis, and potentially fetal death. Similarly, maternal hypercarbia can cause uterine artery vasoconstriction, compromising uterine blood flow and resulting in fetal respiratory acidosis. Conversely, hypocapnia can reduce uterine blood flow and trigger fetal acidosis. Uterine hypertension, often resulting from increased uterine irritability, can further decrease uteroplacental blood flow, highlighting the need for careful management of maternal ventilation and blood pressure.
Risk of Preterm Labor
Preterm labor is a notable risk associated with non-obstetric surgery during pregnancy. Studies have reported an increased incidence of spontaneous abortion, premature labor, and preterm delivery following such surgeries. The risk is particularly elevated when the surgery involves uterine manipulation or when there is an underlying maternal condition, such as sepsis. Research from as early as 1977 demonstrated significantly higher fetal mortality rates when complications like peritonitis occurred during appendicitis in pregnancy. The risk for preterm labor is lowest during the second trimester and for surgeries that do not involve direct uterine manipulation.
When premature labor occurs, the use of tocolytics may be considered to delay delivery. Although the effectiveness of tocolytics in the context of non-obstetric surgery remains debated, they may still be used prophylactically in the third trimester for surgeries involving the lower abdomen or pelvis, particularly in cases of inflammatory conditions. Volatile anesthetic agents, while potentially helpful in relaxing the uterus, may cause hypotension at high concentrations, which is undesirable. Alternative tocolytic agents, such as beta-mimetics (e.g., terbutaline), magnesium sulfate, vasodilators (e.g., glyceryl trinitrate), and calcium-channel blockers (e.g., nifedipine), may be chosen based on the clinical scenario.
